PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Detalles Bibliográficos
Autores principales: Barrientos, J. C., Barr, P. M., Mato, A. R., Tam, C. S., Ghia, P., Moreno, C., Kay, N. E., Siddiqi, T., Szafer-Glusman, E., Zhou, C., Neumayr, L., Krigsfeld, G., Wierda, W. G., Shanafelt, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431472/
http://dx.doi.org/10.1097/01.HS9.0000850364.78915.d9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431472/
http://dx.doi.org/10.1097/01.HS9.0000850364.78915.d9

Ejemplares similares